Clinical Trial Update: Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease [Phase 1]

View source ↗

Summary

A Phase 1 trial of CDX-1135 in pediatric and adult patients with Dense Deposit Disease and related glomerulonephritides was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• C3 Glomerulonephritis
• Dense Deposit Disease
• Membranoproliferative Glomerulonephritis Type Ii

Drugs mentioned

• CDX-1135

Snippet

Sponsor: Celldex Therapeutics | Conditions: Dense Deposit Disease, Membranoproliferative Glomerulonephritis Type II | Phase 1 | Status: TERMINATED